An interventional study of Real fNIRS Neurofeedback and Sham-Control fNIRS Neurofeedback in Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Bulimia Nervosa with a site in United States — 14 open to participants now, 20 under way, none of them phase 3. Bulimia Nervosa · United States.
Among the 87 studies in Bulimia Nervosa with a site in United States, this one is the 40th largest by planned enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2024, is one of 56 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 69th registered.
173 studies on the registry are indexed under Bulimia Nervosa; 38 are open to participants now.
Browse Bulimia Nervosa studies →14 of the 87 studies in Bulimia Nervosa with a site in United States are open now. Recruiting first, the newest first:
Trustees of Dartmouth College · Sites in United States
Ages 18–70
University of Kansas · Sites in United States
Ages 18–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–55 · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Milton S. Hershey Medical Center · Sites in United States
Ages 12–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Bulimia Nervosa studies recruiting now, 9 (29%) set no upper age limit and 20 (65%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 2 · Phase 4 1
First in 1998; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 121 interventional studies indexed under Bulimia Nervosa.
Median enrollment 42 across the 68 interventional studies, 89 across the 17 observational. Of the 62 that completed or were terminated, 13 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 87 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 6 studies filed under Bulimia Nervosa — fewer than ten, so there is no comparison to draw.
7 of the studies in Bulimia Nervosa with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05509257Children's Mercy Hospital Kansas CityNaltrexone Neuroimaging in Teens With Eating Disorders | 2026-12 |
| NCT03393039University of California, San DiegoEffects of Negative Affect in Individuals With Binge Eating Episodes | 2027-01 |
| NCT05473013Nemours Children's ClinicOptimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization | 2027-01 |
| NCT05056597University of California, San DiegoIncentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa | 2027-01 |
| NCT06000774University of California, San DiegoTherapeutic Ketogenic Diet in Anorexia Nervosa | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 87 studies in Bulimia Nervosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.
The purpose of this study is to examine the effects of PFC neurofeedback during eating in women with bulimia nervosa (BN) using fNIRS. Specifically, the study aims 1) to demonstrate ventrolateral PFC (vlPFC) neurofeedback target engagement in women with BN using fNIRS; and 2) to link changes in PFC activation to changes in inhibitory control and eating-related symptoms.
Data will be collected from women with BN who will be randomly assigned to one of two group conditions (real or sham-control neurofeedback during eating). Participation includes a phone screening assessment, psychodiagnostic assessment, one in-person evaluation, one neurofeedback session, behavioral tasks, online questionnaires before and after the neurofeedback session, and a remote follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the experimental arm will see their true, real-time brain activation (i.e., active real-time neurofeedback) during the neurofeedback session. This activation will be displayed to the participant as a thermometer that will increase as brain activation in the target region increases.
Other: Real fNIRS Neurofeedback
Participants assigned to the sham-control arm will see false feedback (or a fake signal) that is not connected to their right vlPFC activation during the neurofeedback session.
Other: Sham-Control fNIRS Neurofeedback
Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
Functional near-infrared spectroscopy (fNIRS)-measured neural activation and connectivity
The investigators will evaluate changes in PFC neural activation and connectivity as a function of neurofeedback.
Time frame: approximately 1 hour
Go/no-go task performance
Participants will complete a go/no-go task 1 week before and 1 week after the neurofeedback session to measure inhibitory control. Participants behavioral performance on the go/no-go task will be determined by the percentage of incorrect responses made as they are prompted to react to different pictorial stimuli. Participants' percentages of error can range from 0% to 100%. A higher percentage indicates a lower behavioral performance on the task.
Time frame: 2 weeks
Number of loss-of-control eating and purging episodes
Frequency of loss-of-control eating and purging episodes. Participants will self-report on how often loss-of-control eating and purging episodes occur using electronic daily diaries in the week before and the week after the neurofeedback session.
Time frame: 2 weeks
Severity of loss-of-control eating scale
Severity of loss-of-control eating. Participants will rate the severity of their feelings of control over eating and purging episodes on a Likert-type scale from 0-10. Higher score indicates greater severity of loss of control.
Time frame: 2 weeks
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting information: Statistical analysis plan
Time frame: Immediately following publication and ending 5 years following article publication.
Access criteria: Researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. Proposals should be directed to laura.berner@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years after article publication via direct request to the investigator.
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.
Of 62 non-industry interventional studies with no phase under Bulimia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 43 months is close to that.
Counting every sponsor, half of 64 studies reached it within 43 months; a quarter within 18 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →